<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30279510</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">2045-2322</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>8</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>02</Day>                    </PubDate>                </JournalIssue>                <Title>Scientific reports</Title>                <ISOAbbreviation>Sci Rep</ISOAbbreviation>            </Journal>            <ArticleTitle>The mapping of cancer incidence and mortality trends in the UK from 1980-2013 reveals a potential for overdiagnosis.</ArticleTitle>            <Pagination>                <MedlinePgn>14663</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-018-32844-x</ELocationID>            <Abstract>                <AbstractText>The incidence of cancer in the United Kingdom has increased significantly over the last four decades. The aim of this study was to examine trends in UK cancer incidence and mortality by cancer site and assess the potential for overdiagnosis. Using Cancer Research UK incidence and mortality data for the period (1971-2014) we estimated percentage change in incidence and mortality rates and the incidence-mortality ratio (IMR) for cancers in which incidence had increased &gt;50%. Incidence and mortality trend plots were used to assess the potential for overdiagnosis. Incidence rates increased from 67% (uterine) to 375% (melanoma). Change in mortality rates ranged from -69% (cervical) to +239% (liver). The greatest divergences occurred in uterine (IMR = 132), prostate (IMR = 9.6), oral (IMR = 9.8) and thyroid cancer (IMR = 5.3). Only in liver cancer did mortality track incidence (IMR = 1.1). For four cancer sites; uterine, prostate, oral and thyroid, incidence and mortality trends are suggestive of overdiagnosis. Trends in melanoma and kidney cancer suggest potential overdiagnosis and an underlying increase in true risk, whereas for cervical and breast cancer, trends may also reflect improvements in treatments or earlier diagnosis. A more detailed analysis is required to fully understand these patterns.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Oke</LastName>                    <ForeName>Jason L</ForeName>                    <Initials>JL</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-3467-6677</Identifier>                    <AffiliationInfo>                        <Affiliation>University of Oxford, Nuffield Department of Primary Care Health Sciences, Oxford, OX2 6GG, United Kingdom. jason.oke@phc.ox.ac.uk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>O'Sullivan</LastName>                    <ForeName>Jack W</ForeName>                    <Initials>JW</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-3629-2546</Identifier>                    <AffiliationInfo>                        <Affiliation>University of Oxford, Nuffield Department of Primary Care Health Sciences, Oxford, OX2 6GG, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Perera</LastName>                    <ForeName>Rafael</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>University of Oxford, Nuffield Department of Primary Care Health Sciences, Oxford, OX2 6GG, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nicholson</LastName>                    <ForeName>Brian D</ForeName>                    <Initials>BD</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0661-7362</Identifier>                    <AffiliationInfo>                        <Affiliation>University of Oxford, Nuffield Department of Primary Care Health Sciences, Oxford, OX2 6GG, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>02</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Sci Rep</MedlineTA>            <NlmUniqueID>101563288</NlmUniqueID>            <ISSNLinking>2045-2322</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2016 Oct 20;34(30):3672-3679</RefSource>                <PMID Version="1">27601555</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer Care (Engl). 2017 May;26(3):</RefSource>                <PMID Version="1">28426170</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Urol. 2015 Dec;194(6):1583</RefSource>                <PMID Version="1">26582661</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2014 Nov 6;371(19):1765-7</RefSource>                <PMID Version="1">25372084</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2017 Apr 4;317(13):1338-1348</RefSource>                <PMID Version="1">28362912</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ. 2014 Feb 11;348:g366</RefSource>                <PMID Version="1">24519768</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2015 Jan 2;347(6217):78-81</RefSource>                <PMID Version="1">25554788</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2015 Nov;51(16):2296-303</RefSource>                <PMID Version="1">26296293</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2015 Dec;51(18):2833-41</RefSource>                <PMID Version="1">26589973</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Urol. 2017 Dec;72(6):899-907</RefSource>                <PMID Version="1">28844371</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2005 Jun 4-10;365(9475):1927-33</RefSource>                <PMID Version="1">15936419</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Virology. 2009 Feb 20;384(2):260-5</RefSource>                <PMID Version="1">19135222</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2010 May 5;102(9):605-13</RefSource>                <PMID Version="1">20413742</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2008 Jun;19(6):1187-94</RefSource>                <PMID Version="1">18325921</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Dermatol. 2009 Nov;161(5):977-9</RefSource>                <PMID Version="1">19785614</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer Prev. 2016 Mar;25(2):149-54</RefSource>                <PMID Version="1">25793918</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2006 Jun 7;98(11):748-56</RefSource>                <PMID Version="1">16757699</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Med Screen. 2012 Jun;19(2):89-93</RefSource>                <PMID Version="1">22653575</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2015 Dec 1;113(11):1632</RefSource>                <PMID Version="1">26103571</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2015 Mar 3;112(5):943-7</RefSource>                <PMID Version="1">25647015</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ. 2012 May 28;344:e3502</RefSource>                <PMID Version="1">22645185</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2008 Feb 16;371(9612):569-78</RefSource>                <PMID Version="1">18280327</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ. 2005 Sep 3;331(7515):481</RefSource>                <PMID Version="1">16081427</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ Evid Based Med. 2018 Feb;23(1):1-3</RefSource>                <PMID Version="1">29367314</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Dermatol. 2009 Sep;161(3):630-4</RefSource>                <PMID Version="1">19519827</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 1993 Apr 29;328(17):1237-43</RefSource>                <PMID Version="1">8464435</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2004 Jan 21;96(2):99-106</RefSource>                <PMID Version="1">14734699</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2011 Dec 6;105 Suppl 2:S77-81</RefSource>                <PMID Version="1">22158327</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2006 Aug 7;95(3):401-5</RefSource>                <PMID Version="1">16832417</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2009 Mar 26;360(13):1320-8</RefSource>                <PMID Version="1">19297566</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Pathol Jpn. 1991 Sep;41(9):680-4</RefSource>                <PMID Version="1">1776467</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2009 Mar 4;101(5):296-305</RefSource>                <PMID Version="1">19244173</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30279510</ArticleId>            <ArticleId IdType="doi">10.1038/s41598-018-32844-x</ArticleId>            <ArticleId IdType="pii">10.1038/s41598-018-32844-x</ArticleId>            <ArticleId IdType="pmc">PMC6168593</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>